Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Richard C. Burrell"'
Publikováno v:
Journal of Labelled Compounds and Radiopharmaceuticals. 64:477-481
Non-alcoholic steatohepatitis (NASH) is the most chronic liver condition in the western population and is fueled by the obesity and type 2 diabetes epidemic. Pegbelfermin (1), a PEGylated human fibroblast growth factor 21 (FGF21) analogue, has previo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e21dca13b64e015d23ce9a4550b1b279
https://doi.org/10.1002/jlcr.3940
https://doi.org/10.1002/jlcr.3940
Publikováno v:
Journal of labelled compoundsradiopharmaceuticalsREFERENCES. 65(4)
Censavudine is a nucleoside reverse transcriptase inhibitor (NRTI) explored clinically by Bristol Myers Squibb for the treatment of human immunodeficiency virus-1 (HIV-1). As part of the development process, a carbon-14 labeled analog was synthesized
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::394f5d8a3e4c3074702293303273a4f6
https://pubmed.ncbi.nlm.nih.gov/35106813
https://pubmed.ncbi.nlm.nih.gov/35106813
Publikováno v:
Journal of labelled compoundsradiopharmaceuticalsREFERENCES. 64(12)
Non-alcoholic steatohepatitis (NASH) is the most chronic liver condition in the western population and is fueled by the obesity and type 2 diabetes epidemic. Pegbelfermin (1), a PEGylated human fibroblast growth factor 21 (FGF21) analogue, has previo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0ca0802511e49c827d50721ff56f00fc
https://pubmed.ncbi.nlm.nih.gov/34386991
https://pubmed.ncbi.nlm.nih.gov/34386991
Publikováno v:
Journal of Labelled Compounds and Radiopharmaceuticals. 59:665-672
BMS-725519, BMS-811064, and BMS-812204 are potent and selective central cannabinoid receptor antagonists that have been investigated for the treatment of human obesity. To further understand their biotransformation profiles, radiolabelled and stable-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32bfb424e56216596b016b51bd8d04bc
https://doi.org/10.1002/jlcr.3433
https://doi.org/10.1002/jlcr.3433
Publikováno v:
Journal of Labelled Compounds and Radiopharmaceuticals. 59:164-170
Daclatasvir is a novel hepatitis C virus NS5A inhibitor developed by Bristol-Myers Squibb and marketed as Daklinza®. The need to support the development of daclatasvir required the synthesis of carbon-14 labeled material for use in human absorption,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::06415e6975e0eec39250aaed12f5f550
https://doi.org/10.1002/jlcr.3386
https://doi.org/10.1002/jlcr.3386
Autor:
Richard C. Burrell, John A. Easter, Lata Venkatarangan, Naiyu Zheng, Hong Shen, Jinping Gan, Hamza Kandoussi, Samuel J. Bonacorsi, Weiqi Chen, Rasa Santockyte, Jianing Zeng, Yan J Zhang
Publikováno v:
Bioanalysis. 10(18)
Aim: A robust LC–MS/MS assay was developed to quantify endogenous 1, 14-tetradecanedioic acid (TDA) and 1, 16-hexadecanedioic acid (HDA) in human plasma as potential biomarkers for evaluating drug–drug interactions mediated by the hepatic drug tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a37585e9d4cd847a6c6b1d791f2fa1c2
https://pubmed.ncbi.nlm.nih.gov/30215261
https://pubmed.ncbi.nlm.nih.gov/30215261
Publikováno v:
Journal of Labelled Compounds and Radiopharmaceuticals. 58:361-369
The stabilization of microtubules using epothilones represents a novel mechanism of action to treat Alzheimer's disease. Epothilone D is one such microtubule-stabilizing drug that has been investigated by Bristol-Myers Squibb. An important step in th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e1ef087fa88ee14e6b43ac6474380a36
https://doi.org/10.1002/jlcr.3312
https://doi.org/10.1002/jlcr.3312
Autor:
John Ryan, Anne-Françoise Aubry, Roger Demers, Hamza Kandoussi, Mark E. Arnold, Pathanjali Kadiyala, Chanda Baker, Richard C. Burrell, Bing He, Jianing Zeng, Timothy Eley, Laura Cojocaru, John A. Easter, Janice Pursley, Jian Wang, Hao Jiang
Publikováno v:
Journal of Pharmaceutical and Biomedical Analysis. 107:409-418
Dual or triple combination regimens of novel hepatitis C direct-acting antivirals (DAA, daclatasvir, asunaprevir, or beclabuvir) provide high sustained virological response rates and reduced frequency of resistance compared to clinical monotherapy. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7e414b4e759e3185780cc9bce96f222
https://doi.org/10.1016/j.jpba.2015.01.027
https://doi.org/10.1016/j.jpba.2015.01.027
Autor:
Samuel J. Bonacorsi, Richard E. Olson, Michael P. Cassidy, John A. Easter, Richard C. Burrell, Kevin W. Gillman
Publikováno v:
Journal of Labelled Compounds and Radiopharmaceuticals. 57:600-605
Bristol-Myers Squibb and others are developing drugs that target novel mechanisms to combat Alzheimer's disease. γ-Secretase inhibitors are one class of potential therapies that have received considerable attention. (R)-2-(4-Chloro-N-(2-fluoro-4-(1,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::139cabb0783cb1db008b8e942a973aea
https://doi.org/10.1002/jlcr.3224
https://doi.org/10.1002/jlcr.3224
Publikováno v:
Journal of Labelled Compounds and Radiopharmaceuticals. 56:632-636
Stable isotope-labeled [(13) C4 ]entecavir (1) was prepared in 11 steps. Commercially available [(13) C]guanidine hydrochloride and diethyl[1,2,3-(13) C3 ]malonate were condensed to yield 2-amino[2,4,5,6-(13) C4 ]pyrimidine-4,6-diol (8). This was con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e9569fb1d1f44a9f260016862077e4b3
https://doi.org/10.1002/jlcr.3064
https://doi.org/10.1002/jlcr.3064